This company is no longer active
CBIO Stock Overview
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Catalyst Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.67 |
| 52 Week High | US$11.10 |
| 52 Week Low | US$2.83 |
| Beta | 1.29 |
| 1 Month Change | 6.01% |
| 3 Month Change | 46.09% |
| 1 Year Change | -8.39% |
| 3 Year Change | -90.64% |
| 5 Year Change | -95.39% |
| Change since IPO | -99.62% |
Recent News & Updates
Recent updates
Catalyst Biosciences declares special one-time dividend of $1.43
Aug 25Catalyst Biosciences: Shareholders Should Reap Benefits From Owning The Stock
Aug 15Catalyst Biosciences plans to distribute $65M cash to stockholders
Jun 29Companies Like Catalyst Biosciences (NASDAQ:CBIO) Could Be Quite Risky
Jan 11
Circling Back On Catalyst Biosciences
Dec 08Shareholders May Not Be So Generous With Catalyst Biosciences, Inc.'s (NASDAQ:CBIO) CEO Compensation And Here's Why
Jun 03Catalyst Biosciences (NASDAQ:CBIO) Will Have To Spend Its Cash Wisely
May 18Catalyst Biosciences EPS misses by $0.12, beats on revenue
May 06Would Shareholders Who Purchased Catalyst Biosciences' (NASDAQ:CBIO) Stock Five Years Be Happy With The Share price Today?
Mar 09We're Hopeful That Catalyst Biosciences (NASDAQ:CBIO) Will Use Its Cash Wisely
Feb 01Catalyst Biosciences announces closing of $50M capital raise
Jan 29Do Institutions Own Catalyst Biosciences, Inc. (NASDAQ:CBIO) Shares?
Dec 28Catalyst Biosciences' MarzAA fast track'd for episodic bleeding in hemophilia patients
Dec 02What We Learned About Catalyst Biosciences' (NASDAQ:CBIO) CEO Pay
Dec 02Catalyst Biosciences (CBIO) Presents At Stifel 2020 Virtual Healthcare Conference - Slideshow
Nov 18Catalyst Biosciences: After 2 Fundraisings, A Lengthy Wait For Pivotal Trial Data Is Next
Nov 14Shareholder Returns
| CBIO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 18.6% | 0.4% | 1.5% |
| 1Y | -8.4% | -2.7% | 22.4% |
Return vs Industry: CBIO underperformed the US Biotechs industry which returned -4.2% over the past year.
Return vs Market: CBIO underperformed the US Market which returned 14.1% over the past year.
Price Volatility
| CBIO volatility | |
|---|---|
| CBIO Average Weekly Movement | 20.1% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 18.0% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CBIO's share price has been volatile over the past 3 months.
Volatility Over Time: CBIO's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 7 | Nassim Usman | www.catalystbiosciences.com |
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally. It develops Hydronidone, that has completed phase 1 clinical trial for the treatment of nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease. The company was founded in 2002 and is headquartered in South San Francisco, California.
Catalyst Biosciences, Inc. Fundamentals Summary
| CBIO fundamental statistics | |
|---|---|
| Market cap | US$19.42m |
| Earnings (TTM) | -US$44.24m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.4x
P/E RatioIs CBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CBIO income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$1.97m |
| Gross Profit | -US$1.97m |
| Other Expenses | US$42.27m |
| Earnings | -US$44.24m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -17.47 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CBIO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/10/31 03:06 |
| End of Day Share Price | 2023/10/30 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Catalyst Biosciences, Inc. is covered by 7 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| George Zavoico | B. Riley Securities, Inc. |
| Gbolahan Amusa Benz | Chardan Capital Markets, LLC |
| Kevin DeGeeter | Ladenburg Thalmann & Company |